SWM
NBIX icon

Selective Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Selective Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-85
Closed -$9K – 505
2022
Q3 		$9K Hold
85
– – ﹤0.01% 531
2022
Q2 		$8K Buy
+85
New +$7.84K ﹤0.01% 585

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Selective Wealth Management's NBIX Position: Q4 2022 in Review

Selective Wealth Management sold out of Neurocrine Biosciences (NBIX) in Q4 2022, closing a stake of 85 shares — an estimated $9K sold.

Selective Wealth Management first reported a position in NBIX in Q2 2022 and held it in 2 quarters. The position peaked at $9K in Q3 2022. 529 funds tracked by Wall St. Rank hold NBIX as of Q4 2022.

  • Selective Wealth Management reported no remaining Neurocrine Biosciences position as of Q4 2022 after selling out during the quarter.
  • Selective Wealth Management sold 85 Neurocrine Biosciences shares in Q4 2022, an estimated $9K.
  • Selective Wealth Management first reported a position in Neurocrine Biosciences in Q2 2022 and held it in 2 quarters.
  • Selective Wealth Management's Neurocrine Biosciences position peaked at $9K in Q3 2022.
  • 529 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2022.

Based on Selective Wealth Management's 13F filing for Q4 2022, filed 23 Jan 2023.